Healthcare / BiotechnologyWarsaw
$14.76
-1.12 (-7.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-121.6M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$341M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-188.0%
↓Gross Margin
76.2%
↑Debt/Equity
1.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.9%
FCF CAGR
—
FCF margin
-195.3%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.3M · net income $-101.2M · FCF $-121.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.3M | $62.3M | $78.0M | $46.9M | $38.9M |
| Net Income | $-101.2M | $-101.2M | $-111.4M | $-92.1M | $-83.8M |
| EBITDA | $-81.3M | $-81.3M | $-96.8M | $-81.0M | $-65.2M |
| EPS | -4.40 | -4.40 | -4.80 | -4.00 | -4.60 |
| Gross Margin | 76.2% | 76.2% | 74.9% | 62.5% | 55.3% |
| Operating Margin | -156.2% | -156.2% | -156.4% | -207.8% | -178.4% |
| Net Margin | -162.6% | -162.6% | -142.9% | -196.6% | -215.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.33 | 1.33 | 0.44 | 0.00 | 0.01 |
| Current Ratio | 2.26 | 2.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-121.6M | $-121.6M | $-135.4M | $-93.1M | $12.0M |
| Returns | |||||
| ROE | -188.0% | -188.0% | -73.2% | -35.5% | -24.4% |
| Valuation | |||||
| P/B | 6.34 | 6.34 | 5.90 | 4.98 | 2.92 |
| Growth & Yield | |||||
| Revenue Growth | -20.2% | -20.2% | 66.4% | 20.3% | — |
| EPS Growth | 8.3% | 8.3% | -20.0% | 13.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.80 → -4.40
Residual
-52.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.